ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
出版年份 2020 全文链接
标题
ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 1, Pages 241
出版商
MDPI AG
发表日期
2020-12-29
DOI
10.3390/ijms22010241
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Combining microenvironment normalization strategies to improve cancer immunotherapy
- (2020) Fotios Mpekris et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.
- (2019) Jeeyun Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Trends and Challenges in Tumor Anti-Angiogenic Therapies
- (2019) József Jászai et al. Cells
- Trends in clinical development for PD-1/PD-L1 inhibitors
- (2019) Jia Xin Yu et al. NATURE REVIEWS DRUG DISCOVERY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aptamers in the Therapeutics and Diagnostics Pipelines
- (2018) Harleen Kaur et al. Theranostics
- Anti-Angiogenics: Current Situation and Future Perspectives
- (2018) Katja Zirlik et al. Oncology Research and Treatment
- Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis
- (2016) Dongheon Lee et al. mAbs
- Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer
- (2015) F. Kuhnert et al. CANCER RESEARCH
- Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts
- (2014) Kiersten Marie Miles et al. PLoS One
- Anti-VEGF Therapies in the Clinic
- (2013) K. L. Meadows et al. Cold Spring Harbor Perspectives in Medicine
- Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer
- (2012) Muxing Kang et al. CANCER LETTERS
- Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration
- (2012) Matthew Ohr et al. EXPERT OPINION ON PHARMACOTHERAPY
- Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF- B Activity
- (2012) T. Kuramoto et al. MOLECULAR CANCER THERAPEUTICS
- MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo
- (2012) D. W. Jenkins et al. MOLECULAR CANCER THERAPEUTICS
- DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
- (2011) J.-L. Li et al. CANCER RESEARCH
- VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
- (2011) W.-K. You et al. CANCER RESEARCH
- Time-Course Imaging of Therapeutic Functional Tumor Vascular Normalization by Antiangiogenic Agents
- (2011) Q. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
- (2010) H. Hashizume et al. CANCER RESEARCH
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor-Initiating Cell Frequency
- (2009) Timothy Hoey et al. Cell Stem Cell
- Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications
- (2009) Ji-Liang Li Frontiers in Bioscience-Landmark
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started